Sangamo rises as FDA grants Fast Track

Sangamo Therapeutics (NASDAQ: SGMO) announced that the U.S. FDA granted Fast Track Designation to ST-503 for the treatment of intractable pain from small fiber neuropathy (SFN).

The designation may enable more frequent FDA interactions and could make ST-503 eligible for Accelerated Approval or Priority Review if criteria are met. ST-503 is an investigational epigenetic regulator currently in the Phase 1/2 STAND study, with patient recruitment underway and first dosing expected in the coming months. Sangamo previously presented nonclinical data showing durability, potency, selectivity and a favorable safety profile in nonhuman primates.

https://www.stocktitan.net/news/SGMO/sangamo-therapeutics-receives-u-s-fda-fast-track-designation-for-st-nkxgnizqo5uf.html